Abstracts tagged "Systemic sclerosis"

Abstract Number: 1517 • ACR Convergence 2023
Comparing Deep Neural Network to Modified Rodnan Skin Score in a Trial for Belumosudil in Systemic Sclerosis Patients
Baran Gunes¹, Lucy Duran Camacho¹, Shawn Cowper², Gauri Panse², Elizabeth Bundschuh³, Alyssa Williams⁴, Nicolas Page⁵, Mary Karns⁶, Kathleen Aren⁶, Niki Pradhan⁷, Elana Bernstein⁸, Sarah Fantus⁹, Elizabeth Volkmann¹⁰, Heather Bukiri¹⁰, Chase Correia¹¹, Francis Wilson¹, Seamus Mawe¹², J. Matthew Mahoney¹³, Monique Hinchcliff¹⁴ and Rui Wang¹⁵, ¹Yale University School of Medicine, New Haven, CT, ²Yale School of Medicine - Dermatopathology, New Haven, CT, ³Yale University School of Medicine, New York, NY, ⁴Yale University School of Medicine, Winchester, MA, ⁵Yale University School of Medicine, Salem, CT, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷Columbia University Irving Medical Center, New York, NY, ⁸Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ⁹Kansas City Physician Partners- Center for Rheumatic Disease, Kansas City, MO, ¹⁰University of California Los Angeles, Los Angeles, CA, ¹¹Riverside Medical Group, Hampton, VA, ¹²The Jackson Laboratory, Bar Harbor, ME, ¹³Jackson Laboratory, Bar Harbor, ME, ¹⁴Yale School of Medicine, Westport, CT, ¹⁵Sanofi, Cambridge, MA
Background/Purpose: We previously published a proof-of-principle study demonstrating the potential utility of computer vision (Deep Neural Network/DNN) methods applied to stained skin biopsy sections from…
Abstract Number: 1699 • ACR Convergence 2023
Immunosuppression with Targeted Therapies Reduces Morbidity and Mortality in Pre-Capillary Pulmonary Hypertension Associated with Systemic Sclerosis: A EUSTAR Analysis
Cosimo Bruni¹, Havard Fretheim², Lorenzo Tofani³, Yannick Weber¹, Eric Hachulla⁴, Patricia Carreira⁵, Dilia Giuggioli⁶, Paolo Airò⁷, Elise Siegert⁸, Ulf Müller-Ladner⁹, marco Matucci Cerinic¹⁰, Gabriela Riemekasten¹¹, Carmen Pilar Simeon-Aznar¹², Jeska de Vries-Bouwstra¹³, Lesley Ann Saketkoo¹⁴, Joerg Distler¹⁵, Alexandra Balbir-Gurman¹⁶, Ivan Castellvi¹⁷, Elisabetta Zanatta¹⁸, Vanessa Smith¹⁹, Christopher Denton²⁰, Britta Maurer²¹, Alessandro Giollo¹⁸, Florenzo Iannone²², Lorenzo Dagna²³, Marie-Elise Truchetet²⁴, Masataka Kuwana²⁵, Yannick ALLANORE²⁶, Yoshiya Tanaka²⁷, Mickael Martin²⁸, Edoardo Rosato²⁹, Ana Maria Gheorghiu³⁰, Francesco Del Galdo³¹, Kamal Solanki³², Alessandra Vacca³³, CATARINA RESENDE³⁴, SUSANA VIEIRA³⁵, Laszlo Czirjak³⁶, Marko Barisic³⁷, Francesco Paolo Cantatore³⁸, valeria Riccieri³⁹, Kristofer Andréasson⁴⁰, Lorinda Chung⁴¹, Carolina Muller⁴², Daniela OPRIS-BELINSKI⁴³, Simona Rednic⁴⁴, Petros Sfikakis⁴⁵, Yair Levy⁴⁶, Anna Maria Hoffmann-Vold⁴⁷, Oliver Distler¹, Vivien Hsu⁴⁸, Stefan Heitmann⁴⁹, Gianluca Moroncini⁵⁰, Michele Iudici⁵¹, Joerg Henes⁵², Ellen De Langhe⁵³, Ariane Herrick⁵⁴ and Carlomaurizio Montecucco⁵⁵, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Scleroderma Unit, Rheumatology Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy, ⁷Spedali Civili di Brescia, Scleroderma UNIT, UOC Reumatologia ed Immunologia Clinica, Piazzale Spedali Civili 1, 25123, Brescia, Italy, ⁸Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁹Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ¹⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹¹University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ¹²Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ¹³Leiden University Medical Center, Leiden, Netherlands, ¹⁴University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, ¹⁵Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁶Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, ¹⁷Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Sant Just Desvern, Spain, ¹⁸Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Padova, Padua, Italy, ¹⁹Ghent University Hospital, Gent, Belgium, ²⁰University College London, London, United Kingdom, ²¹University Hospital Bern, University Bern, Bern, Switzerland, ²²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²³Ospedale San Raffaele, Milano, Italy, ²⁴Bordeaux University Hospital, Bordeaux, France, ²⁵Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²⁶Université Paris Cité, Paris, France, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Department of Internal Medicine, INSERM U1313, Poitiers University, Poitiers University Hospital, Poitiers, France, ²⁹Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy, ³⁰Department of Internal Medicine and Rheumatology, Ion Cantacuzino Clinical Hospital, Bucharest, Romania, ³¹University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³²Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ³³II Chair of Rheumatology, University of Cagliari-Policlinico Universitario, Monserrato, Italy, ³⁴Serviço de Reumatologia e Doenças Ósseas Metabólicas, Hospital de Santa Maria, CHLN, Lisboa, Portugal, ³⁵Hospital Fernando Fonseca, Lisbon, Portugal, ³⁶Dept. Rheumatol Immunol, Medical School, university of Pecs, Pecs, Hungary, ³⁷Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Zagreb, Croatia, ³⁸Rheumatology Clinic – Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy, ³⁹Department of Clinical, Internal and Cardiovascular Specialities, Sapienza University of Rome, Roma, Italy, ⁴⁰Lund University, Lund, Sweden, ⁴¹Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Woodside, CA, ⁴²Federal University of Parana, CURITIBA / PR, Brazil, ⁴³Saint Mary Hospital, Bucharest, Romania, ⁴⁴Prof Dr Simona Rednic, Cluj, Romania, ⁴⁵National Kapodistrian University of Athens Medical School, Athens, Greece, ⁴⁶Meir Medical Center, Autoimmune Research Laboratory, Kfar-Saba, Israel, ⁴⁷Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ⁴⁸Rutgers-RWJ Medical School, South Plainfield, NJ, ⁴⁹Department of Rheumatology, Marienhospital Stuttgart, Böheimstrasse 37, D-70199, Stuttgart, Germany, ⁵⁰Marche Polytechnic University, Ancona, Italy, ⁵¹Division of Rheumatology, Department of Internal Medicine Specialties, Geneva University Hospitals, Geneva, Switzerland, ⁵²University Hospital Tuebingen, Tuebingen, Germany, ⁵³Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium, ⁵⁴University of Manchester, Salford, United Kingdom, ⁵⁵Unità Operativa e Cattedra di Reumatologia, IRCCS Policlinico S Matteo, Pavia, Italy
Background/Purpose: Systemic sclerosis (SSc) associated pre-capillary pulmonary hypertension (precapPH) is a severe condition that requires prompt treatment. Although immunosuppressants (IMS) are standard of care for…
Abstract Number: 2362 • ACR Convergence 2023
Identification of Protein Biomarkers Associated with the Severity and Risk of Progression of Interstitial Lung Disease in VEDOSS and Established Systemic Sclerosis Patients
Thierry Sornasse¹, Vishal Kakkar², Rebecca Ross³, Sunhwa Kim⁴ and Francesco Del Galdo⁵, ¹AbbVie, Inc., North Chicago, IL, ²University of Leeds, Leeds, United Kingdom, ³Medicine and Health, University of Leeds, Leeds, United Kingdom, ⁴AbbVie, Inc., South San Francisco, CA, ⁵University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom
Background/Purpose: Pulmonary Fibrosis (PF) is one of the primary causes of systemic sclerosis (SSc)-related death. Hence, monitoring and predicting the course of PF in SSc…
Abstract Number: 0615 • ACR Convergence 2023
Prevalence of Barrett’s Esophagus in Patients with Systemic Sclerosis
FNU Rida Ul Jannat¹, Devanshu Verma¹ and Laila Sakkal², ¹West Virginia University Hospital, Morgantown, WV, ²West Virginia University, Morgantown, WV
Background/Purpose: Gastrointestinal manifestations of systemic sclerosis are common and include luminal dysmotility. Esophageal aperistalsis (scleroderma esophagus) presents with dysphagia and reflux; and can predispose patients…
Abstract Number: 0633 • ACR Convergence 2023
Prediction of Progressive Fibrosing Interstitial Lung Disease in Systemic Sclerosis Patients: Insight from the CRDC Cohort Study
Min Hui¹, Xinwang Duan², Jiaxin Zhou³, Mengtao Li³, Qian Wang⁴, Jiuliang Zhao¹, Yong Hou¹, Dong Xu⁵ and xiaofeng Zeng⁴, ¹Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China, ⁴Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁵Department of Rheumatology, Peking Union Medical College, Beijing, China
Background/Purpose: Systemic sclerosis (SSc) patients can develop progressive fibrosing interstitial lung disease (PF-ILD), linked to a poor outcome. This study aims to establish a reliable…
Abstract Number: 0656 • ACR Convergence 2023
Concordance and Prognostic Relevance of Different Definitions of Systemic Sclerosis Interstitial Lung Disease Progression
enrico De Lorenzis¹, Francesco Del Galdo², gerlando Natalello¹, Stefano Di Donato², lucrezia verardi¹, Vishal Kakkar², pier giacomo Cerasuolo¹, Francesco Varone³, Luca Richeldi³, Maria Antonietta D'Agostino¹ and Silvia Bosello¹, ¹Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy, ²University of Leeds - Leeds Institute of Rheumatic and Muskuloskeletal Medicine, Leeds, United Kingdom, ³Division of Pulmonology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in systemic sclerosis (SSc) is a common complication that has varied progression rate and prognosis. Different progression definitions include minimal…
Abstract Number: 0789 • ACR Convergence 2023
Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis
Monica Yang¹, Shuo Liu², Seoyeon Lee³, Sarah French¹, Paul Wolters¹ and Francesco Boin⁴, ¹University of California San Francisco, San Francisco, CA, ²Fourth Hospital of China Medical University, Shenyang, China, ³Yale University School of Medicine, New Haven, CT, ⁴Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Peripheral blood leukocyte telomere length (PBL-TL) has been associated with disease and organ specific morbidity and mortality in conditions associated with pulmonary fibrosis including…
Abstract Number: 0951 • ACR Convergence 2023
Single Cell Analysis of Transitional B Cells in Systemic Sclerosis Highlights Defective Peripheral Tolerance
Claire Beesley¹, Nina Goldman¹, David Abraham¹, Christopher Denton¹, Rizgar Mageed² and Voon Ong³, ¹University College London, London, United Kingdom, ²Queen Mary University of London, London, United Kingdom, ³UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Transitional B cells comprise a distinct population of B cells that have recently migrated to the periphery from the bone marrow. In systemic sclerosis…
Abstract Number: 1519 • ACR Convergence 2023
Renal Complications Following Autologous Stem Cell Transplantation for Systemic Sclerosis
Malcolm MacKenzie¹, Harry Atkins² and Nancy Maltez¹, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Rapidly progressive diffuse systemic sclerosis (SSc) is a devastating autoimmune disease with high morbidity and mortality. Autologous hematopoietic stem cell transplantation (AHSCT) is recognized…
Abstract Number: 1700 • ACR Convergence 2023
Incidence and Risk Factors for New Onset of Interstitial Lung Disease in Systemic Sclerosis: A EUSTAR Analysis
liubov Petelytska¹, Arthiha Velauthapillai², Lorenzo Tofani³, Eric Hachulla⁴, Ulf Müller-Ladner⁵, Elise Siegert⁶, Yannick ALLANORE⁷, Gabriela Riemekasten⁸, Christina Bergmann⁹, Radim Becvar¹⁰, Kamal Solanki¹¹, Branimir Anic¹², Simona Rednic¹³, Bojana Stamenkovic¹⁴, Lisa Stamp¹⁵, Joerg Distler¹⁶, Madelon Vonk¹⁷, Jeska de Vries-Bouwstra¹⁸, Anna Maria Hoffmann-Vold¹⁹, marco Matucci Cerinic²⁰, Oliver Distler²¹ and Cosimo Bruni²¹, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Department of Statistics, Computer Science, Applications, University of Florence, Florence, Italy, ⁴University of Lille, Lille, France, ⁵Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, ⁶Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁷Université Paris Cité, Paris, France, ⁸University Clinic Schleswit-Holstein (UKSH), Lübeck, Germany, ⁹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ¹⁰Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Praha, Czech Republic, ¹¹Department of Rheumatology, Te Whatu Ora Health New Zealand Waikato, Hamilton, New Zealand, ¹²Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Zagreb, School of Medicine, University Hospital Center Zagreb, Kišpatićeva 12, 10 000, Zagreb, Croatia, ¹³Prof Dr Simona Rednic, Cluj, Romania, ¹⁴Institut Niska Banja, Niska Banja, Serbia, ¹⁵University of Otago, Christchurch, New Zealand, ¹⁶Clinic for Rheumatology University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, ¹⁷Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁸Leiden University Medical Center, Leiden, Netherlands, ¹⁹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²⁰Unit of Immunology, Rheumatology, Allergy and Rare diseases, IRCCS San Raffaele Hospital, Milan, Milan, Italy, ²¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Although prevalence of interstitial lung disease (ILD) in systemic sclerosis (SSc) and associated risk factors are established, less is known about its incidence and…
Abstract Number: 2364 • ACR Convergence 2023
Circulating CTHRC1 Levels Are Associated with Disease Severity and Predict Survival in Systemic Sclerosis
Monica Yang¹, Seoyeon Lee², Lisa Hazelwood³, Dean Sheppard¹, Francesco Boin⁴ and Paul Wolters¹, ¹University of California San Francisco, San Francisco, CA, ²Yale University School of Medicine, New Haven, CT, ³AbbVie, Inc., North Chicago, IL, ⁴Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Despite recent advances in systemic sclerosis (SSc), there remains a paucity of clinically actionable biomarkers to assess disease severity and predict progression. Collagen triple…
Abstract Number: 0616 • ACR Convergence 2023
Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study
Lea Meir¹, Tegveer Sandhu², Weiwei Chi² and Gabriela Santiago², ¹Icahn School of Medicine, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…
Abstract Number: 0634 • ACR Convergence 2023
Prevalence and Associations of Anaemia in Systemic Sclerosis Patients in a National Observational Cohort; Results from the Australian Scleroderma Cohort Study
Raychel Barallon¹, Gene-Siew Ngian¹, Diane Apostolopoulos¹, Dylan Hansen², Kathleen Morrisroe³, Wendy Stevens⁴, Susanna Proudman⁵, Mandana Nikpour⁶ and Joanne Sahhar¹, ¹Monash Health and Monash University, Clayton, Australia, ²Department of Rheumatology, St Vincent’s Hospital Melbourne, Fitzroy, Australia, ³The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, ⁴Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, ⁵Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia, ⁶The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: Anaemia in systemic sclerosis (SSc) is under-studied and under-characterised. Its prevalence amongst SSc patients is not well described, nor are its effects on outcomes…
Abstract Number: 0657 • ACR Convergence 2023
The Value of the Six-Minute Walk Test in Detecting Cardiopulmonary Involvement in Patients with Systemic Sclerosis
Saad Ahmed, Sophie Liem, Jeska de Vries-Bouwstra and Thomas Huizinga, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Cardiopulmonary involvement (CPI) in systemic sclerosis (SSc) is associated with significant morbidity and mortality. Early detection and timely treatment is warranted. The Six-minute walk…
Abstract Number: 0791 • ACR Convergence 2023
Expression of TL1A, Inflammatory, and Fibrotic Pathways in Patients with Diffuse Systemic Sclerosis
Heather Llewellyn¹, Lam (Alex) Tsoi², Minghua Wu³, Kristina Grigaityte¹, Tony (Yong) Wang¹, James R. Seibold¹, Ernesto Muñoz-Elias¹, Dinesh Khanna⁴ and Johann E. Gudjonsson⁴, ¹Prometheus Biosciences, Inc., San Diego, CA, ²Department of Dermatology and Biostatistics, University of Michigan, Ann Arbor, MI, ³Department of Internal Medicine, Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a multiorgan disease characterized by systemic vascular injury, inflammation, and fibrosis. While SSc mainly affects the skin, pulmonary manifestations such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].